Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada.

Pharmacogenetics and genomics - 1 Feb 2021

Fan Mikayla, Yarema Mark C, Box Adrian, Hume Stacey, Aitchison Katherine J, Bousman Chad A

Abstract excerpt

OBJECTIVES: To facilitate decision-making and priority-setting related to Alberta's Pharmacogenomics (PGx) testing implementation strategy by identifying gene-drug pairs with the highest potential impact on prescribing practices in Alberta. PATIENTS AND METHODS: Annual drug dispensing data for Alberta from 2012 to 2016 for 57 medications with PGx-based prescribing guidelines were obtained, along with population...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alberta
Share to Clinical Decision-Making

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 CYP2D6

Share to Drug-Related Side Effects and Adverse Reactions

Share to Pharmaceutical Preparations

Share to Pharmacogenomic Testing

Share to Precision Medicine

Source

Identifiers

PMID: 32826605
DOI: 10.1097/FPC.0000000000000418

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada.PMID 32826605Read ↗

Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems.Semantic proximity Read ↗

Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada.Semantic proximity Read ↗

Pharmacogenetics: Opportunities for the All of Us Research Program and Other Large Data Sets to Advance the FieldSemantic proximity Read ↗

Disease-drug database for pharmacogenomic-based prescribing.Semantic proximity Read ↗

Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy UsersSemantic proximity Read ↗

Genotype-predicted drug response phenotypes and their co-occurrence with dispensed medicines among 738,531 participants in the UK Our Future Health studySemantic proximity Read ↗

Recommendations for pharmacogenetic testing in clinical practice guidelines in the USSemantic proximity Read ↗

Evaluation of population-level pharmacogenetic actionability in Alabama.Semantic proximity Read ↗

Real-World Characterization of Psychiatric Pharmacogenomic Test Ordering and Clinical Relevance in Adults and Children.Semantic proximity Read ↗

Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study.Semantic proximity Read ↗

Evaluating genotype-treatment interactions for high-risk medications in British general practice: a retrospective cohort study using UK Biobank.Semantic proximity Read ↗

Planning for a national effort to enable and accelerate discoveries in pharmacogenetics: the NIH Pharmacogenetics Research Network.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.